Dashboard
Manage Tickers

BGNEBeiGene, Ltd.

Nasdaq beigene.com


$ 153.38 $ -3.15 (-2.01 %)    

Tuesday, 30-Apr-2024 13:20:08 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 427.97 $ -4.29 (-0.99 %)
DIA $ 380.02 $ -2.20 (-0.58 %)
SPY $ 505.42 $ -2.49 (-0.49 %)
TLT $ 88.43 $ -0.04 (-0.05 %)
GLD $ 212.32 $ -1.59 (-0.74 %)
$ 156.53
$ 157.88
$ 130.00 x 100
$ 0.00 x 0
$ 151.60 - $ 157.88
$ 126.97 - $ 266.67
185,728
na
16.37B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-26-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-27-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-02-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 02-28-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 03-22-2017 12-31-2016 10-K
30 11-10-2016 09-30-2016 10-Q
31 08-10-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

tracking-last-weeks-top-performers-are-these-15-large-cap-stocks-in-your-portfolio-april-21-27-2024
Tracking Last Week's Top Performers: Are T...
04/28/2024 22:18:08

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

evaluating-beigene-insights-from-6-financial-analysts
Evaluating BeiGene: Insights From 6 Financ...
04/24/2024 18:01:41

td-cowen-maintains-buy-on-beigene-raises-price-target-to-236
TD Cowen Maintains Buy on BeiGene, Raises ...
04/24/2024 17:26:08

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $235 to $236.

healthstream-reports-upbeat-results-joins-spotify-ryder-system-and-other-big-stocks-moving-higher-on-tuesday
HealthStream Reports Upbeat Results, Joins...
04/23/2024 14:50:19

the-european-commission-approves-beigenes-tislelizumab-for-non-small-cell-lung-cancer-across-three-indications-including-first-and-second-line-use
The European Commission Approves BeiGene's...
04/23/2024 10:08:22

b-of-a-securities-maintains-neutral-on-beigene-lowers-price-target-to-1643
B of A Securities Maintains Neutral on Bei...
04/08/2024 16:34:50

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $179.3 to...

genfleet-therapeutics-announced-clinical-trial-collaboration-and-supply-agreement-with-beigene-switzerland-to-start-a-combination-study-of-gfh009-and-brukinsa-zanubrutinib-in-phase-1b2-trial-for-diffuse-large-b-cell-lymphoma
Genfleet Therapeutics Announced Clinical T...
03/28/2024 11:14:09

4-analysts-assess-beigene-what-you-need-to-know
4 Analysts Assess BeiGene: What You Need T...
03/27/2024 15:00:50

bernstein-maintains-market-perform-on-beigene-lowers-price-target-to-161
Bernstein Maintains Market Perform on BeiG...
03/27/2024 08:48:58

Bernstein analyst Rebecca Liang maintains BeiGene (NASDAQ:BGNE) with a Market Perform and lowers the price target from $196 ...

lululemon-issues-weak-outlook-joins-nike-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Lululemon Issues Weak Outlook, Joins Nike ...
03/22/2024 09:40:40

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.

fda-approves-beigenes-first-drug-candidate-produced-through-its-immuno-oncology-program-for-esophageal-cancer
FDA Approves BeiGene's First Drug Candidat...
03/15/2024 17:01:52

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy...

beigene-secures-fda-approval-for-tevimbra-for-treatment-of-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-after-prior-chemotherapy
BeiGene Secures FDA Approval For TEVIMBRA ...
03/14/2024 20:29:34

TEVIMBRA will be available in the U.S. in the second half of 2024. The FDA is also reviewing Biologics License Applications (BL...

fda-approves-beigenes-tevimbra-as-of-march-13-2024
FDA Approves Beigene's Tevimbra As Of Marc...
03/14/2024 18:13:44

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232

why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Clover Health Investments Shares Are T...
03/13/2024 17:18:56

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

first-doses-of-brukinsa-provided-to-patients-with-chronic-lymphocytic-leukemia-in-low--and-middle-income-countries-under-collaboration-of-max-foundation-beigene-and-beigene-foundation
First Doses Of BRUKINSA Provided To Patien...
03/13/2024 12:07:56

Armenia and Nepal are the first of 29 countries to receive BRUKINSA

beauty-health-posts-upbeat-sales-joins-siga-technologies-maxcyte-and-other-big-stocks-moving-higher-in-wednesdays-pre-market-session
Beauty Health Posts Upbeat Sales, Joins SI...
03/13/2024 10:16:13

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

fda-conditionally-approves-expanded-use-of-beigenes-combination-drug-for-certain-type-of-blood-cancer
FDA Conditionally Approves Expanded Use Of...
03/08/2024 15:02:38

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination ...

Core News & Articles
Beigene Said It Filed Patent Infringement ...
03/08/2024 11:09:52

-8-K

beigene-announces-fda-accelerated-approval-of-brukinsa-for-treatment-of-relapsed-or-refractory-follicular-lymphoma
BeiGene Announces FDA Accelerated Approval...
03/07/2024 22:20:04

beigene-announces-efficacy-analysis-comparing-brukinsa-to-acalabrutinib-in-relapsed-or-refractory-chronic-lymphocytic-leukemia
BeiGene Announces Efficacy Analysis Compar...
02/29/2024 15:07:19

Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION